Prothena (PRTA)
NASDAQ:PRTA
Top Page
Prothena
(NASDAQ:PRTA)
Select Model
Select Model
Rating:51Neutral
Price Target:
$10.50
▼(-0.76% Downside)
Action:ReiteratedDate:02/28/26
The score is held back primarily by weak financial performance (inconsistent revenue, heavy recent losses, and persistent cash burn) and bearish-to-soft technicals. This is partly offset by a relatively strong earnings-call backdrop (partner programs moving into Phase III and a solid cash position) and a modestly supportive buyback authorization, while valuation remains difficult to anchor due to negative earnings and no dividend yield.
Positive Factors
Partnered Phase III Programs
Advancement of partner-led programs into large Phase III trials represents durable de-risking and validation: partners carry substantial development costs, create multi-year milestone and royalty optionality, and materially increase potential long-term revenue streams if trials succeed.
Negative Factors
Sustained cash burn
Multi-year negative operating and free cash flow creates structural funding pressure: absent consistent milestone inflows or product revenue, the company will need to rely on milestone receipts, partnerships, or capital markets, raising dilution and execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Partnered Phase III Programs
Advancement of partner-led programs into large Phase III trials represents durable de-risking and validation: partners carry substantial development costs, create multi-year milestone and royalty optionality, and materially increase potential long-term revenue streams if trials succeed.
Read all positive factors
Prothena (PRTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$569.55M
Dividend YieldN/A
Average Volume (3M)732.47K
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue Growth-91.16%
EPS Growth-112.24%
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.40
Shares Outstanding53,832,980
10 Day Avg. Volume686,318
30 Day Avg. Volume732,465
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.83
Price to Sales (P/S)53.08
P/FCF Ratio-3.14
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue28.04
Enterprise Value/Gross Profit-13.45
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$21.50Price Target Upside103.21% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.78
Revenue Forecast (FY)$111.77M
Prothena Business Overview & Revenue Model
Company Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized ant...
How the Company Makes Money
Prothena primarily generates revenue through collaboration and license arrangements rather than product sales (it is a clinical-stage company and, to the extent it has no commercialized products, product revenue is null). Under these partnerships,...
Prothena Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much revenue each business segment generates, highlighting which parts of the company are driving growth and which may need strategic adjustments.
Shows how much revenue each business segment generates, highlighting which parts of the company are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyProthena Earnings Call Summary
Earnings Call Date:Feb 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.Positive Updates
Two Partner Programs Advanced to Phase III
Roche advanced prasinezumab into the Phase III PARAISO trial (≈900 participants; primary completion expected in 2029). Novo Nordisk advanced coramitug into the Phase III CLEOPATTRA trial (≈1,280 patients; primary completion expected in 2029).
Negative Updates
ARIA‑E and Safety Profile Concerns for PRX012
PRX012 ASCENT reported ARIA‑E rates described as 'noncompetitive' relative to FDA‑approved anti‑Aβ antibodies, prompting a strategic pivot to a PRX012‑transferrin receptor (TfR) program to try to improve the ARIA profile.
Read all updates
Q4-2025 Updates
Positive
Negative
Two Partner Programs Advanced to Phase III
Roche advanced prasinezumab into the Phase III PARAISO trial (≈900 participants; primary completion expected in 2029). Novo Nordisk advanced coramitug into the Phase III CLEOPATTRA trial (≈1,280 patients; primary completion expected in 2029).
Read all positive updates
Company Guidance
Prothena's 2026 guidance calls for full‑year net cash used in operating and investing activities of $50–55 million, an estimated net loss of $67–72 million (which includes about $24 million of noncash share‑based compensation), and an expected year‑end cash, cash equivalents and restricted cash balance of approximately $255 million at the midpoint; this guidance does not include up to $105 million of potential aggregate clinical milestone payments from partners in 2026. For context, Prothena closed 2025 with $308.4 million in cash (as of Dec 31, 2025), reported 2025 net cash used in operating and investing activities of $163.7 million (favorable to prior guidance of $170–178 million), a 2025 net loss of $244.1 million (in line with guidance of $240–248 million), had 53.8 million ordinary shares outstanding as of Feb 12, 2026, and a simple capital structure with zero debt.Prothena Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.68M | 135.16M | 91.37M | 53.91M | 200.58M |
| Gross Profit | 5.98M | 135.16M | 91.37M | 53.91M | 200.58M |
| EBITDA | -197.13M | -153.67M | -190.11M | -130.81M | 73.09M |
| Net Income | -244.09M | -122.31M | -147.03M | -116.95M | 66.97M |
Balance Sheet | |||||
| Total Assets | 326.80M | 547.11M | 696.38M | 758.03M | 609.37M |
| Cash, Cash Equivalents and Short-Term Investments | 307.53M | 471.39M | 618.83M | 710.41M | 579.09M |
| Total Debt | 13.86M | 10.84M | 11.84M | 6.47M | 12.33M |
| Total Liabilities | 46.33M | 60.18M | 135.02M | 135.99M | 143.32M |
| Stockholders Equity | 280.47M | 486.93M | 561.37M | 622.04M | 466.04M |
Cash Flow | |||||
| Free Cash Flow | -163.72M | -150.35M | -136.72M | -109.28M | 92.03M |
| Operating Cash Flow | -163.58M | -150.05M | -133.91M | -108.82M | 92.61M |
| Investing Cash Flow | -138.00K | -298.00K | -2.77M | -464.00K | -575.00K |
| Financing Cash Flow | -139.00K | 1.55M | 45.10M | 241.46M | 190.33M |
Prothena Technical Analysis
Positive
10.58
Price Trends
9.23
Positive
9.54
Positive
8.97
Positive
Market Momentum
0.33
Negative
67.81
Neutral
96.74
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTA, the sentiment is Positive. The current price of 10.58 is above the 20-day moving average (MA) of 9.44, above the 50-day MA of 9.23, and above the 200-day MA of 8.97, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 67.81 is Neutral, neither overbought nor oversold. The STOCH value of 96.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRTA.
Prothena Risk Analysis
Prothena disclosed 62 risk factors in its most recent earnings report. Prothena reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prothena Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $437.65M | 15.08 | 16.22% | ― | 118.02% | ― | |
60 Neutral | $745.68M | -8.29 | -41.94% | ― | 1255.21% | 74.58% | |
56 Neutral | $570.09M | 5.95 | 74.63% | ― | 240.47% | ― | |
55 Neutral | $1.32B | ― | -23.29% | ― | ― | 79.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $569.55M | -2.11 | -73.00% | ― | -91.16% | -112.24% | |
45 Neutral | $2.92B | -34.11 | -72.65% | ― | ― | 13.80% |
* Healthcare Sector Average
PRTA
Prothena
10.50
0.28
2.74%
LXRX
Lexicon Pharmaceuticals
1.72
1.21
237.25%
XOMA
XOMA Royalty Corporation
36.74
16.77
83.98%
ZVRA
Zevra Therapeutics
9.47
2.57
37.25%
CRVS
Corvus Pharmaceuticals
15.10
12.12
406.71%
ALMS
Alumis Inc.
23.05
16.57
255.71%
Prothena Corporate Events
Business Operations and StrategyStock BuybackFinancial Disclosures
Prothena Announces $100 Million Share Repurchase Program
Positive
Feb 27, 2026
On February 27, 2026, Prothena announced that its board had authorized a share repurchase plan allowing the company to buy back up to $100 million of its ordinary shares, with the program running through December 31, 2026 and able to be suspended ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.